Medicus Pharma Ltd. Common Stock (MDCX)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Medicus Pharma, I see a clinical-stage biotech. It is developing SKNJCT-003, a Phase 2 asset for basal cell carcinoma, and has a collaboration with Gorlin Syndrome Alliance. That is a scientific gamble, not a proven business, and I prefer businesses with durable moats and predictable cash. There is no revenue reported in the filed periods, and losses have widened: in FY2023 net income was -$5.3M, in FY2024 -$11.2M, and in FY2025 -$47.3M. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was -$11.6M. Trailing free cash flow was -$29.3M, a -14.1% FCF yield on the $207.2M market cap at the 2026-10-13 close. FairStock calculations show ROE -7,446.11%, ROCE -110.67%, debt-to-equity 146.79, Piotroski 1/9, and Altman Z 0.19. The FairStock Score is 13/100, and because the company lost money in each of the last three years, the computed Lynch category is none. Valuation is negative on earnings, with P/E -1.39 at that close, and there is no book value metric. The 52-week range of $0.14 to $8.45 shows extreme speculation. A negative beta of -0.48 is unusual but not a substitute for profits. Growth is not revenue growth; it is growth in losses. The margin of safety is absent. I would need evidence of trial success, controlled cash burn, and a much lower price to become interested. Until then, it remains a lottery ticket, not a compounding machine.

In plain English: Medicus Pharma is a small healthcare company trying to develop a treatment for basal cell carcinoma, a type of skin cancer. It has no reported revenue in the periods shown and has been losing money, with losses growing. The stock price looks very high for a business with no profits yet, so it mostly reflects hopes about future testing rather than current financial strength.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer